In the BioHarmony Drug Report Database
Pirfenidone
Esbriet (pirfenidone) is a small molecule pharmaceutical. Pirfenidone was first approved as Esbriet on 2011-02-27. It is used to treat pulmonary fibrosis in the USA. It has been approved in Europe to treat idiopathic pulmonary fibrosis. Esbriet’s patents are valid until 2037-03-28 (FDA).
Trade Name
|
Esbriet |
|---|---|
Common Name
|
pirfenidone |
ChEMBL ID
|
CHEMBL1256391 |
Indication
|
idiopathic pulmonary fibrosis, pulmonary fibrosis |
Drug Class
|
Image (chem structure or protein)